Ads
related to: 2025 regulatory conferences today
Search results
Results From The WOW.Com Content Network
We should expect a lot less regulatory headwinds in 2025 for AI given David Sacks will be the AI and crypto czar for the new administration. This is likely to even result in the repeal of ...
The federal government maintains a “regulatory agenda” of all regulations under development by executive branch agencies. [1] The requirement to list rules likely to have a significant economic impact on a substantial number of small entities arises under statute, [1] and the requirement to list all other rules arises under Executive Order 12866 § 4(b).
The legislation that created the CFPB gave it sole authority over those issues among US regulators. Warren was a driver behind the creation of the agency in the wake of the 2008-2009 financial crisis.
Certain American television events in 2025 have been scheduled. Events listed include television show debuts, finales, and cancellations; channel launches, closures, and re-brandings; stations changing or adding their network affiliations; information on controversies, business transactions, and carriage disputes; and deaths of those who made various contributions to the medium.
U.S. Vice President JD Vance outlined on Tuesday the artificial intelligence policies of President Donald Trump's administration, prioritising innovation, de-regulation, protection of free speech ...
In 2012, at the margins of the 65th World Health Assembly conference in May the Minister of Health of Brazil proposed an agenda to create a new coalition of Heads of Agency "to address current and emerging human medicine regulatory and safety challenges globally, strategically and in an ongoing, transparent, authoritative and institutional manner."
Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested ...
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP ®)—today ...